How long do you have to take Wegovy, and what happens if you stop?

You're three months in and wondering whether this is permanent

That feeling usually arrives around week 12. The nausea from the early doses has settled, the appetite shift is real, and the question shifts from "does this work" to "do I have to take this forever". It is one of the most common things people bring to a prescriber, and the honest answer requires looking at what the trial data actually showed.

The STEP 4 trial, which had participants stop semaglutide after 20 weeks and then tracked them for a further 48 weeks, found that weight regain began almost immediately after stopping. By the end of the follow-up period, participants had regained around two-thirds of the weight they had lost. The NHS medicines information for semaglutide reflects this: Wegovy is described as a long-term treatment, not a short course. That is not a sales line; it is a physiological reality. The hormonal and metabolic drivers of weight gain do not go away once a goal weight is reached.

There is no single "right" duration that applies to everyone. Some people reach a stable weight, make lasting changes to their eating patterns during treatment, and work with their prescriber to taper off carefully. Others need to continue indefinitely to maintain health gains. The decision belongs to you and a clinician who knows your picture, not to a generic timeline. For more on when Wegovy starts producing visible results, that question has its own detailed answer.

What the NICE two-year rule actually means for you

If you are accessing semaglutide through the NHS, NICE's appraisal of Wegovy (TA875) recommends it for a maximum of two years, within a specialist weight management service that includes dietary and activity support alongside the medicine. That two-year ceiling is part of the NHS commissioning framework, not a clinical verdict that the medicine stops working or becomes unsafe after 24 months.

Private prescribing operates differently. There is no regulatory two-year cap on private Wegovy prescriptions. A GPhC-registered prescriber can continue treatment beyond two years if clinical review supports it: if you are still benefiting, tolerating the medicine, and the balance of benefit and risk remains favourable. The flip side is that a private prescriber can also recommend stopping or pausing if your circumstances change, you reach a clinically stable point, or you are planning pregnancy (semaglutide is not recommended during pregnancy, breastfeeding, or while actively trying to conceive).

One practical note: if you are timing repeat orders around payday or planning ahead for a holiday where you will need your pen before you travel, it is worth factoring in the clinical review step. At nume, every repeat is assessed by a prescriber before it is dispatched, so building in a working day for that review is sensible.

Stopping Wegovy: what to expect and how to plan

Stopping abruptly is generally not dangerous in the way stopping some other medicines can be. But it is not neutral either. Appetite typically increases relatively quickly once semaglutide clears your system, and without a plan for managing that shift, weight regain can begin within weeks. The NHS notes that the treatment works best alongside reduced-calorie eating and increased activity, and those lifestyle elements become even more important as a buffer when treatment ends.

If you are thinking about stopping, the conversation to have is not "can I stop" but "how do I stop well". That means talking to your prescriber about whether a gradual taper makes sense (evidence on tapering is limited, but some prescribers prefer it to abrupt cessation), what to watch for in the first few months after stopping, and what support is available. You can find an overview of the broader question of how long to stay on Wegovy alongside related guidance about typical treatment periods for different goals.

For people who do regain weight after stopping, restarting is sometimes appropriate, again, subject to clinical review. The titration schedule would typically restart from the beginning rather than jumping to a previously used dose. A prescriber at a registered service like nume can advise whether restarting is suitable based on your history and current health.

Planning duration from the start: how to have this conversation at your consultation

The most useful thing you can do at the beginning of treatment is frame this as an open question rather than assuming a fixed endpoint. Ask your prescriber: what would prompt you to recommend stopping? What results over six months would suggest we continue? The Wegovy overview sets out the general treatment framework, and the first-month results data can calibrate realistic early expectations.

NICE's guidance states that if you have not lost at least 5% of your starting weight after six months on the maintenance dose, continuing treatment should be reviewed. That benchmark applies both within NHS services and as a reasonable clinical reference point in private care. It is not a cliff-edge (a prescriber might find a clinical reason to extend the trial) but it is the evidence-based signal to reassess.

Cost over a long treatment course is a genuine consideration. The Wegovy cost page covers what private treatment typically involves across multiple months, so you can plan realistically. Duration and budget are part of the same conversation, and there is nothing wrong with raising both at your consultation. If you would like that conversation with a clinician, you can speak to our prescribers through a free consultation.